[
    [
        {
            "time": "2018-10-30",
            "original_text": "Pharma Stock Roundup: MRK, BMY Q3 Earnings, Cancer Data Presentations at ESMO",
            "features": {
                "keywords": [
                    "MRK",
                    "BMY",
                    "Q3 Earnings",
                    "Cancer Data",
                    "ESMO"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 10,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-10-25",
            "original_text": "What's in the Cards for Glaxo (GSK) This Earnings Season?",
            "features": {
                "keywords": [
                    "Glaxo",
                    "GSK",
                    "Earnings Season"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-10-31",
            "original_text": "Celgeneâ€™s Revlimid and Pomalyst Saw Solid Q3 Growth",
            "features": {
                "keywords": [
                    "Celgene",
                    "Revlimid",
                    "Pomalyst",
                    "Q3 Growth"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 10,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-10-26",
            "original_text": "Gilead (GILD) Beats on Q3 Earnings & Sales, Updates View",
            "features": {
                "keywords": [
                    "Gilead",
                    "GILD",
                    "Q3 Earnings",
                    "Sales",
                    "Updates View"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 10,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-08-02",
            "original_text": "The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default",
            "features": {
                "keywords": [
                    "Gilead",
                    "Q2",
                    "Syndax",
                    "Breast Cancer Drug",
                    "Setback",
                    "Synergy Pharma",
                    "Default"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-11-01",
            "original_text": "Novartis Gets EC Approval For Cosentyx Label Update In Europe - Quick Facts",
            "features": {
                "keywords": [
                    "Novartis",
                    "EC Approval",
                    "Cosentyx",
                    "Label Update",
                    "Europe"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 10,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]